- Home
- TOVX vs XRTX Comparison
TOVX vs XRTX Comparison
Compare TOVX & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOVX
- XRTX
- Stock Information
- Founded
- TOVX 2001
- XRTX 2011
- Country
- TOVX United States
- XRTX Canada
- Employees
- TOVX N/A
- XRTX N/A
- Industry
- TOVX Biotechnology: Pharmaceutical Preparations
- XRTX Pharmaceuticals and Biotechnology
- Sector
- TOVX Health Care
- XRTX Health Care
- Exchange
- TOVX Nasdaq
- XRTX Nasdaq
- Market Cap
- TOVX 3.5M
- XRTX 4.1M
- IPO Year
- TOVX 2006
- XRTX N/A
- Fundamental
- Price
- TOVX $1.21
- XRTX $1.15
- Analyst Decision
- TOVX Strong Buy
- XRTX Strong Buy
- Analyst Count
- TOVX 1
- XRTX 1
- Target Price
- TOVX $6.00
- XRTX $14.00
- AVG Volume (30 Days)
- TOVX 102.1K
- XRTX 16.7K
- Earning Date
- TOVX 11-12-2024
- XRTX 11-15-2024
- Dividend Yield
- TOVX N/A
- XRTX N/A
- EPS Growth
- TOVX N/A
- XRTX N/A
- EPS
- TOVX N/A
- XRTX N/A
- Revenue
- TOVX N/A
- XRTX N/A
- Revenue This Year
- TOVX N/A
- XRTX N/A
- Revenue Next Year
- TOVX N/A
- XRTX N/A
- P/E Ratio
- TOVX N/A
- XRTX N/A
- Revenue Growth
- TOVX N/A
- XRTX N/A
- 52 Week Low
- TOVX $1.14
- XRTX $1.09
- 52 Week High
- TOVX $17.00
- XRTX $7.00
- Technical
- Relative Strength Index (RSI)
- TOVX 37.37
- XRTX 40.84
- Support Level
- TOVX $1.15
- XRTX $1.14
- Resistance Level
- TOVX $1.34
- XRTX $1.25
- Average True Range (ATR)
- TOVX 0.07
- XRTX 0.09
- MACD
- TOVX 0.01
- XRTX 0.01
- Stochastic Oscillator
- TOVX 7.41
- XRTX 10.71
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.